Naoero vs Sur: The number of people with susceptibility test result for rifampicin
Naoero
100
in 2021
Sur
97.1
in 2021
Naoero rank
2nd
Sur rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Naoero
- Sur
How they compare
Naoero currently reports 100 against 97.1 in Sur, a difference of 2.9.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Sur ahead.
Naoero ranks 2nd and Sur ranks 2nd of 146 countries.
Sur has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Naoero | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0 | 86.78 | 86.78 | Sur |
| 2020s | 50 | 97.8 | 47.8 | Sur |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Naoero or Sur?
- Naoero, at 100 against 97.1 in Sur as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Naoero and Sur?
- 2.9, with Naoero ahead.
- How many years of comparable data are there for Naoero and Sur?
- 5 years are reported by both, from 2017 to 2021.
- How do Naoero and Sur rank globally for the number of people with susceptibility test result for rifampicin?
- Naoero ranks 2nd and Sur ranks 2nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.